Zealand Pharma pens $1.2bn AI obesity drug discovery pact with Generate
Zealand Pharma and AI-centric biotech Generate Biomedicines have teamed up to develop protein-based therapeutics for obesity and other metabolic diseases…
14 Oct 2026
MHRA homes in on personalised healthcare and tech in new 2030 strategy
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has devised a new strategy to better harness advancements in personalised healthcare and technology, facilitating improved health access for patients. …
14 Oct 2026
Soufflé Therapeutics snags $135m to bring trio of drugs to the clinic
Soufflé Therapeutics has sweetened up a group of big life science investor names to secure $135m in a Series B financing, which will see the Boston-based biotech take three of…
14 Oct 2026
Charles River partners with Magellan Stem Cells on cell therapy
Charles River Laboratories International (CRL) has collaborated with Australian biotechnology firm Magellan Stem Cells to advance the development and clinical progress of Magellan's regenerative medicine candidate, Zelestrocel. The partnership focuses…
14 Oct 2026
Pfizer partners with Enodia Therapeutics in $500m drug deal
Pfizer and Enodia Therapeutics have announced a research collaboration and licensing deal potentially worth over $500m to discover and develop Sec61 inhibitors. Under the partnership, Enodia Therapeutics will handle initial…
13 Oct 2026
Tremfya rescues J&J’s immunology sales to fuel strong Q3
Johnson & Johnson (J&J) leaned on strong demand for anti-inflammatory drug Tremfya (guselkumab) to offset steep erosion in other areas of its immunology portfolio, resulting in strong overall Q3 performance.…
13 Oct 2026
Roche bets on the RNAi approach for obesity through $1bn Rona deal
Roche has made another bid to enter the increasingly lucrative obesity arena through a licensing deal centred around an RNA interference (RNAi) therapy created by Rona Therapeutics – marking the…